Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06270355 | Stockholm Mammography Risk Stratified Trial(SMART) | not yet recruiting | Phase 3 | 70,000 | Karolinska InstitutetOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06278896 | Early Neutropenic Fever De-escalation of Antibiotics Study(END) | not yet recruiting | Phase 3 | 260 | Brigham and Women's HospitalOTHER | 0 | Feb 26, 2024 | clinicaltrials |
| NCT06268327 | Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy | not yet recruiting | Phase 2 / Phase 3 | 30 | Assiut UniversityOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06254599 | A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC | not yet recruiting | Phase 3 | 255 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT06217042 | HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer | not yet recruiting | Phase 3 | 524 | Fudan UniversityOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT05993559 | Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy | not yet recruiting | Phase 3 | 1,314 | Gangnam Severance HospitalOTHER | 0 | Jan 12, 2024 | clinicaltrials |
| NCT06188455 | Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer | not yet recruiting | Phase 3 | 37 | The First Affiliated Hospital of Xiamen UniversityOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT06146777 | Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy | not yet recruiting | Phase 3 | 468 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Nov 29, 2023 | clinicaltrials |
| NCT06115629 | Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial(SARONG-II) | not yet recruiting | Phase 3 | 952 | University of Dublin, Trinity CollegeOTHER | 5 | Nov 3, 2023 | clinicaltrials |
| NCT06102161 | Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020) | not yet recruiting | Phase 3 | 286 | Fudan UniversityOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06097416 | Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer | not yet recruiting | Phase 3 | 100 | St. James's Hospital, IrelandOTHER | 0 | Oct 25, 2023 | clinicaltrials |
| NCT06095167 | Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC | not yet recruiting | Phase 3 | 476 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06089382 | A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection | not yet recruiting | Phase 3 | 104 | Tongji HospitalOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05914610 | Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer | not yet recruiting | Phase 3 | 100 | Fujian Medical UniversityOTHER | 0 | Aug 25, 2023 | clinicaltrials |
| NCT05990127 | A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer | not yet recruiting | Phase 3 | 642 | AkesoINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05976568 | A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 / Phase 3 | 668 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05970900 | Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST(PIRKER) | not yet recruiting | Phase 3 | 23 | Fujian Medical University Union HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05876832 | A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) | not yet recruiting | Phase 3 | 312 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 0 | May 26, 2023 | clinicaltrials |
| NCT05496166 | The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 348 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05841381 | Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer | not yet recruiting | Phase 3 | 876 | Fudan UniversityOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT05813665 | A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone | not yet recruiting | Phase 3 | 146 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05810623 | Single-Dose Intravesical Chemotherapy After Diagnostic URS(MINERVA) | not yet recruiting | Phase 3 | 394 | David D'AndreaOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05100641 | AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM | not yet recruiting | Phase 3 | 672 | Aivita Biomedical, Inc.INDUSTRY | 0 | Apr 10, 2023 | clinicaltrials |
| NCT05767892 | YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | not yet recruiting | Phase 3 | 350 | Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05780294 | A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC | not yet recruiting | Phase 3 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05717764 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment | not yet recruiting | Phase 3 | 500 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 0 | Feb 8, 2023 | clinicaltrials |
| NCT05718232 | SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)(SEARCH) | not yet recruiting | Phase 3 | 136 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05698186 | Thero2-01S22 in HER2-positive Breast Cancer | not yet recruiting | Phase 3 | 320 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05699746 | CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD | not yet recruiting | Phase 3 | 38 | Zhejiang UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05300945 | HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy | not yet recruiting | Phase 2 / Phase 3 | 200 | Zhixin CaoOTHER | 0 | Dec 6, 2022 | clinicaltrials |
| NCT05524389 | Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions | not yet recruiting | Phase 3 | 624 | Peking Union Medical College HospitalOTHER | 0 | Nov 23, 2022 | clinicaltrials |
| NCT05610332 | Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes | not yet recruiting | Phase 3 | 216 | Fujian Medical UniversityOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT05244798 | Sintilimab Plus NCT or NCRT Versus NCRT for ESCC | not yet recruiting | Phase 3 | 420 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT05427669 | Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)(AFFORD) | not yet recruiting | Phase 3 | 340 | Yanhong DengOTHER | 0 | Oct 7, 2022 | clinicaltrials |
| NCT05489848 | Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation | not yet recruiting | Phase 2 / Phase 3 | 294 | Fudan UniversityOTHER | 0 | Aug 5, 2022 | clinicaltrials |
| NCT05232578 | Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness(ESTABLISH) | not yet recruiting | Phase 3 | 380 | General University Hospital, PragueOTHER | 0 | Aug 3, 2022 | clinicaltrials |
| NCT05484024 | Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 588 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05433597 | A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC | not yet recruiting | Phase 2 / Phase 3 | 172 | Sun Yat-sen UniversityOTHER | 0 | Jun 27, 2022 | clinicaltrials |
| NCT05388500 | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)(PHARE-C) | not yet recruiting | Phase 3 | 800 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT05230771 | Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer | not yet recruiting | Phase 3 | 120 | Fujian Medical UniversityOTHER | 0 | Apr 1, 2022 | clinicaltrials |
| NCT05253170 | Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients | not yet recruiting | Phase 3 | 622 | Seoul National University Bundang HospitalOTHER | 0 | Mar 11, 2022 | clinicaltrials |
| NCT05270824 | Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma | not yet recruiting | Phase 3 | 120 | Fujian Medical UniversityOTHER | 0 | Mar 8, 2022 | clinicaltrials |
| NCT05205902 | TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides(TOTEM-01) | not yet recruiting | Phase 3 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jan 25, 2022 | clinicaltrials |
| NCT05172518 | Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer | not yet recruiting | Phase 3 | 512 | Sun Yat-sen UniversityOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT04973319 | Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy | not yet recruiting | Phase 3 | 450 | Shengjing HospitalOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04384601 | Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer | not yet recruiting | Phase 3 | 246 | Ruijin HospitalOTHER | 1 | Jul 19, 2021 | clinicaltrials |
| NCT04890522 | An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC | not yet recruiting | Phase 2 / Phase 3 | 622 | Sun Yat-sen UniversityOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT04772287 | Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008) | not yet recruiting | Phase 3 | 341 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Feb 26, 2021 | clinicaltrials |
| NCT04215510 | Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT | not yet recruiting | Phase 3 | 286 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Feb 23, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Feb 28, 2024source: clinicaltrials